4594 — BrightPath Biotherapeutics Co Share News
0.000.00%
Last trade - 00:00Table: Brightpath Biotherapeutics -2025/26 parent forecast
Table: Brightpath Biotherapeutics - 9-MTH parent results
Table: Brightpath Biotherapeutics - 6-MTH parent results
Table: Brightpath Biotherapeutics - Q1 parent results
Table: Brightpath Biotherapeutics -2024/25 parent results
Table: Brightpath Biotherapeutics -2024/25 parent forecast
Table: Brightpath Biotherapeutics - 9-MTH parent results
Table: Brightpath Biotherapeutics - 6-MTH parent results
Table: Brightpath Biotherapeutics - Q1 parent results
Table: Brightpath Biotherapeutics -2023/24 parent results
Table: Brightpath Biotherapeutics - 9-MTH parent results
Table: Brightpath Biotherapeutics -2023/24 parent forecast
Table: Brightpath Biotherapeutics - 6-MTH parent results
Table: Brightpath Biotherapeutics - Q1 parent results
Table: Brightpath Biotherapeutics -2022/23 parent results
Brief: Brightpath Biotherapeutics And Artisan Bio Announce Research And Licensing Agreement To Accelerate Development Of Brightpath's Novel Allogeneic Ipsc Derived Cell Therapy Platform Across Multiple Indications
Table: Brightpath Biotherapeutics - 9-MTH parent results
Table: Brightpath Biotherapeutics - 6-MTH parent results
Table: Brightpath Biotherapeutics - Q1 parent results